Clinical Trials Logo

Clinical Trial Summary

This is a multi-center, Phase 1a study to assess the safety, tolerability, PK, and PD of VGA039 following single IV or SC dose administration in healthy subjects and Von Willebrand disease patients.


Clinical Trial Description

This first in human study consists of 2 parts based on the subject population: Part 1 and Part 2. Part 1 is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) evaluation of IV or SC VGA039 or placebo in up to 8 cohorts. Part 2 is an open-label, SAD of SC and IV VGA039 in up to 8 cohorts. All participants will be enrolled, treated, and followed up for 15 weeks (IV SAD) or 8 weeks(SC SAD). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05776069
Study type Interventional
Source Vega Therapeutics, Inc
Contact Clinical Trials
Phone 650-466-8041
Email info@vega-therapeutics.com
Status Recruiting
Phase Phase 1
Start date March 16, 2023
Completion date December 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04398628 - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed NCT03621020 - Clinical Performance Evaluation of T-TAS 01 PL Chip
Recruiting NCT04146376 - Von Willebrand Factor in Pregnancy (VIP) Study
Recruiting NCT03715673 - Von Willebrand Antigen and Activity as Novel Biomarkers of Hemostasis in Inflammatory Bowel Disease
Completed NCT03875924 - REAL-LIFE DATA OF CONSTITUTIONAL VON WILLEBRAND DISEASE IN WESTERN FRANCE (HOPSCOTcH-WILL)
Recruiting NCT03773159 - Development of a Device for Evaluating Primary Hemostasis Under Whole Blood Flow Conditions
Recruiting NCT04119908 - Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases N/A
Not yet recruiting NCT04106323 - A Study of Factor Inhibitors in Adult Patients With Hemophilia and Von Willebrand's Disease in Upper Egypt
Active, not recruiting NCT03853486 - ATHN 9: Severe VWD Natural History Study
Recruiting NCT04344860 - Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial Phase 3
Completed NCT04053699 - Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment
Not yet recruiting NCT06205095 - A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients With VWD Phase 3
Completed NCT04052698 - Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD Phase 3
Recruiting NCT04887324 - Real-life Data of Constitutional Von Willebrand Disease in Western France
Not yet recruiting NCT05916469 - Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study
Completed NCT03078595 - Gingival Bleeding and Von Willebrand Disease Typ 2 and 3
Recruiting NCT03327779 - World Bleeding Disorders Registry
Recruiting NCT03070912 - Frequency of Hemorrhages Associated With the Functional Anomalies of Willebrand Factor in Emergency Patients
Completed NCT04466878 - Prognostic Value of Implementing VCE on Top in Constitutional VWD-patients With GI-bleeding
Recruiting NCT04810702 - Impact of Von Willebrand Factor and Its Multimers on Angiogenesis